FEED (ENvue Medical) NonCurrent Deferred Liabilities: $0.00 Mil (As of Mar. 2026)


FEED ENvue Medical Inc FEED
34 GF Score
Price $0.52
GF Value $5.13
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is ENvue Medical NonCurrent Deferred Liabilities?

ENvue Medical FEED -8.77% 34 NonCurrent Deferred Liabilities is $0.00 Mil as of Mar. 2026. GuruFocus rates FEED with a GF Score™ of 34/100 and a GF Value™ of $5.13 (Possible Value Trap). The stock has 4 warning signs investors should review.

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

ENvue Medical's non-current deferred liabilities for the quarter that ended in Mar. 2026 was $0.00 Mil.

ENvue Medical NonCurrent Deferred Liabilities Related Terms


ENvue Medical NonCurrent Deferred Liabilities Historical Data

* Premium members only.

The historical data trend for ENvue Medical's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ENvue Medical NonCurrent Deferred Liabilities Chart

ENvue Medical Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
NonCurrent Deferred Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.15 0.11 0.02 0.00 0.00

ENvue Medical Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
NonCurrent Deferred Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FEED
34GF Score
ENvue Medical Inc FEED
NonCurrent Deferred Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a NonCurrent Deferred Liabilities of $0.00 Mil mean?
ENvue Medical (FEED) has a NonCurrent Deferred Liabilities of $0.00 Mil as of Mar. 2026. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on ENvue Medical and its competitors.
Is ENvue Medical's NonCurrent Deferred Liabilities too high?
ENvue Medical's current NonCurrent Deferred Liabilities is $0.00 Mil. Overall, ENvue Medical has a GF Score™ of 34/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does ENvue Medical's NonCurrent Deferred Liabilities compare to BTCY and LUDG?
ENvue Medical's NonCurrent Deferred Liabilities of $0.00 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good NonCurrent Deferred Liabilities for a Medical Devices & Instruments company?
A good NonCurrent Deferred Liabilities depends on the Medical Devices & Instruments industry context. However, NonCurrent Deferred Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high NonCurrent Deferred Liabilities mean?
A high NonCurrent Deferred Liabilities can signal that a stock is expensive relative to its fundamentals. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on ENvue Medical and its competitors. ENvue Medical's current NonCurrent Deferred Liabilities is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ENvue Medical stock overvalued right now?
Based on GuruFocus' analysis, ENvue Medical (FEED) is currently considered Possible Value Trap. The stock's GF Value™ is $5.13, compared to a current price of $0.52 — trading 89.8% below its estimated fair value. The current NonCurrent Deferred Liabilities is $0.00 Mil. ENvue Medical's overall GF Score™ is 34/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is NonCurrent Deferred Liabilities calculated?
NonCurrent Deferred Liabilities is calculated from a company's financial statements. For ENvue Medical (FEED), the current NonCurrent Deferred Liabilities is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ENvue Medical (FEED) Overvalued in 2026?

Based on GuruFocus' analysis, ENvue Medical stock appears to be undervalued. The current stock price of $0.52 is trading 89.8% below its estimated GF Value™ of $5.13. GuruFocus considers ENvue Medical to be Possible Value Trap.

Key valuation signals for FEED:

  • NonCurrent Deferred Liabilities: $0.00 Mil
  • GF Value™: $5.13 vs. price of $0.52 (89.8% below fair value)
  • GF Score™: 34/100 with 4 warning signs

No single metric tells the full story. See the FEED stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


ENvue Medical Business Description

Address 969 Pruitt Avenue, Tyler, TX, USA, 77569
ENvue Medical Inc develops medical devices for enhanced navigation in clinical procedures. The company provides personalized navigation technology to assist clinicians in placing feeding tubes safely and efficiently. Its ENvue system uses smart feeding tubes with sensors, body mapping, and continuous visual guidance to confirm accurate positioning and reduce complications like lung misplacement. The company conducted the business through two primary operating segments: NanoVibronix and ENvue. The firm generates the majority of its revenue from NanoVibronix, which derives revenues from selling its products directly to patients as well as through distributor agreements. ENvue derives revenues from selling its Systems and Nasoenteral tubes.
34GF Score

Get the complete analysis for FEED

NonCurrent Deferred Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.52
Price
$5.13
GF Value